Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
Frequently asked questions
What sector does Oragenics Inc (OGEN) operate in?
Oragenics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Oragenics Inc (OGEN) current stock price?
As of the latest data, Oragenics Inc stock price is $0.40, with a previous close of $0.42. Oragenics Inc lost -$0.02 in the last trading session, representing a -4.45% loss.
What is Oragenics Inc (OGEN) current market capitalization?
Oragenics Inc market cap is approximately 1.80 million.
What is Oragenics Inc (OGEN) Earnings Per Share (EPS)?
The trailing EPS is $0.98, and the forward EPS is -$0.69.
What is Oragenics Inc (OGEN) Price-to-Earnings (P/E) ratio?
Oragenics Inc current P/E ratio is 0.41.
What is Oragenics Inc (OGEN) EBITDA?
Oragenics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.58 million.
Does Oragenics Inc (OGEN) pay dividends?
No. Oragenics Inc does not pay a dividend.
When is Oragenics Inc (OGEN) next earnings report?
Oragenics Inc is expected to release its next earnings report on September 30, 2026.
What is Oragenics Inc (OGEN) beta (volatility) score?
Oragenics Inc has a beta of 1.253, suggesting it is more volatile than the market.
